Last reviewed · How we verify
NCT06264544: ZEST-PREP
Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism
NA trial testing zinc, selenium, and L-tyrosine in SEPP1 in Thyrotoxicosis in 150 participants. Not yet recruiting.
15 October 2025
Quick facts
| Lead sponsor | S.LAB (SOLOWAYS) |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 150 |
| Start date | 30 July 2025 |
| Primary completion | 15 October 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- zinc, selenium, and L-tyrosine in SEPP1
- Placebo
Conditions studied
- Thyrotoxicosis — all drugs for Thyrotoxicosis →
Sponsor
S.LAB (SOLOWAYS) — full company profile →
Who can join
Adults 18 to 85, any sex, with Thyrotoxicosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. With an estimated sample size of 150 participants per group, accounting for a 20% dropout rate, the trial seeks to demonstrate the supplement's potential in reducing thyrotoxicosis risk through a genetically-informed approach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06264544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other S.LAB (SOLOWAYS) trials
Trials by the same sponsor.
- NCT06877377 — Study of the Safety and Efficacy of Natural Genome Reconstruction Technology of Hematopoietic Stem Cells in Adult Patien · NA · not yet recruiting
- NCT06877364 — Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases · Phase 1, PHASE2 · completed
- NCT06434077 — Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Br · Phase 3 · not yet recruiting
- NCT06269406 — A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative · NA · not yet recruiting
- NCT06911983 — Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabete · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06264544 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by S.LAB (SOLOWAYS)
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06264544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing